If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.50
Bid: 20.00
Ask: 21.00
Change: -0.25 (-1.20%)
Spread: 1.00 (5.00%)
Open: 20.75
High: 20.75
Low: 20.50
Prev. Close: 20.75
IOF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IO#4 and IO#5 Update

28 Feb 2014 07:01

RNS Number : 1577B
Iofina PLC
28 February 2014
 

 

 

28 February 2014

 

Iofina plc.

("Iofina" or the "Group")

(LSE AIM: IOF)

 

Completion of IO#4 Iodine Extraction Plant

IO#5 on track for completion in March

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, is pleased to announce that the construction of the Group's IO#4 iodine extraction plant based on Iofina's WET® IOSorb™ technology is complete and under the control of Iofina's operation team. The tie-in to the well operator is also complete and has been approved by the operator. The plant is located in the vicinity of IO#2 and IO#3.

 

The Board is pleased to announce that the Group's experienced startup and production staff have taken charge of the facility from construction and fabrication teams on site and are in the process of hydro testing the plant prior to the acceptance of brine water, as well as testing of in-line automation systems. The Group hoped to begin hydro testing at IO#4 earlier in February but was limited by winter storms and cold weather. Operator tie-in was also scheduled to be complete at that time but was delayed due to cold weather in the area.

 

Completion of construction of IO#5 is expected in March and the plant will be turned over to operations staff at that time. Production of iodine for both IO#4 and IO#5 is conditional upon final regulatory inspection and approval. Inspection is expected to occur in mid-March with approval thereafter.

 

Construction of IO#6 continues with completion expected in the 2nd quarter of 2014.

 

Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® and IOsorb™ technology. Today's news follows on from the successful commissioning of the Group's IO#1, IO#2, and IO#3 iodine extraction plants.

 

Commenting on today's news, Iofina's Chief Executive George Lantz commented:"The completion of IO#4 solidifies Iofina's capabilities of constructing and operating multiple plants simultaneously. Production from IO#1-IO#3, shortly to be complemented by IO#4, together with anticipated production from IO5# and IO6#, further advances Iofina as a major player in the iodine market."

 

For further information, please contact:

 

George Lantz, CEO

Iofina plc

Tel: +44 (0) 20 3006 3135

www.iofina.com

 

John Prior/Rupert Krefting/Huw Jeremy

Numis

Tel: +44(0)20 7260 1000

 

Rob Collins

GMP Securities

Tel: +44(0)20 7647 2800

 

Media Contact:

Dominic Barretto/Anna Legge

Yellow Jersey PR Limited

Tel: +44(0) 7768 537 739

 

About Iofina

 

Iofina specializes in the exploration and production of iodine, iodine specialty chemical derivatives, and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb™ technology. Iofina has iodine production operations in the United States, specifically in Texas, Montana, and Oklahoma. The Group has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes in Europe, North America and Asia. The Group utilizes its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCTRMLTMBITBAI
Date   Source Headline
2nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.